|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||13.67 - 13.72|
|52-week range||13.67 - 13.72|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Earnings date||13 May 2021 - 17 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The big shareholder groups in Trillium Therapeutics Inc. ( TSE:TRIL ) have power over the company. Insiders often own a...
Unfortunately, capturing that type of gain typically means investing while the company is still small and its outcome is uncertain. Trillium Therapeutics (NASDAQ: TRIL), Vaxart (NASDAQ: VXRT), and Twist Biosciences (NASDAQ: TWST) have ambitions so big, they could produce these life-changing returns from the big-risk, big-reward portion of a diversified portfolio. Jan Skvarka, who Trillium introduced as CEO near the end of 2019, has said the company's long-term goal is to challenge chemotherapy.
What do playing right field in baseball, deep-sea fishing, and investing in small biotech stocks have in common? For shareholders of bluebird bio (NASDAQ: BLUE), Sage Therapeutics (NASDAQ: SAGE), and Trillium Therapeutics (NASDAQ: TRIL), spring announcements may pierce the monotony with updates on key drug development programs. After those stocks' recent struggles, management teams and shareholders are hoping the news will get their share prices moving back toward previous highs.